Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2022

Bhaskaran Divyalakshmi, Bateman Kathryn

Abstract excerpt

The triple combination of Elexacaftor-Tezacaftor-Ivacaftor (ELX-TEZ-IVA) has been shown to markedly improve lung function in persons with cystic fibrosis (pwCF). An important adverse effect of the drug is rash, which was reported in clinical trials and highlighted in case reports. Our report demonstrates a similar adverse event with the drug in one of our patients with spontaneous resolution of the rash not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Exanthema

Share to Mutation

Source

Identifiers

PMID: 35840534
DOI: 10.1016/j.jcf.2022.06.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment.PMID 35840534Read ↗

Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.Semantic proximity Read ↗

Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis.Semantic proximity Read ↗

CFTR modulator drug desensitization: Preserving the hope of long term improvement.Semantic proximity Read ↗

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.Semantic proximity Read ↗

Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.Semantic proximity Read ↗

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series.Semantic proximity Read ↗

Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis.Semantic proximity Read ↗

Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor in an individual with cystic fibrosis caused by a N1303K CFTR variant and infected with Mycobacterium abscessusSemantic proximity Read ↗

Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.